Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10476MR)

This product GTTS-WQ10476MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10476MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8866MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ9273MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ4068MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ3115MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ11184MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ1187MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ12248MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ6015MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 1275
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW